Global Research Trends on the Links Between NfL and Neurological Disorders: A Bibliometric Analysis and Review

Overview

Journal Heliyon

Specialty Social Sciences

Date 2024 Aug 19

PMID 39157316

Authors

Zhengxi Song

Shan Zhang

Hongyu Pan

BingShuang Hu

Xinlian Liu

Jia Cui

LuShun Zhang

Affiliations

Soon will be listed here.

Abstract

Background: The global incidence of neurological diseases has been on the rise, creating an urgent need for a validated marker. Neurofilament Light Chain (NfL) holds promise as such a marker and has garnered significant attention in the field of neurological diseases over the past decades.

Methods: Corresponding articles from 2013 to 2023 were collected from the Web of Science database, and data were analyzed by CiteSpace and VOSviewer software.

Results: A total of 1350 articles were collected from 296 countries/regions, involving 7246 research organizations. Since 2013, among the top ten institutions and authors with the highest number of published papers, the most are from the US and the UK. The United States leads in the number of published papers, but England holds a more momentous position, because it has higher IF. Henrik Zetterberg is the most influential scholar in the field.

Conclusions: The output of papers mainly relies on researchers from developed countries, and scholars from the United States and England have contributed the largest number of papers. Until now, the importance of NfL in neurological diseases has attracted global attention. In addition, NfL contributes to the potential diagnosis of various neurological disorders and can be used to improve the accuracy of differential diagnosis and prognostic assessment as well as predict the response to treatments. More and more in-depth studies are highly needed in the future.

References

Preische O, Schultz S, Apel A, Kuhle J, Kaeser S, Barro C . Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease. Nat Med. 2019; 25(2):277-283. PMC: 6367005. DOI: 10.1038/s41591-018-0304-3. View

Gentil B, Tibshirani M, Durham H . Neurofilament dynamics and involvement in neurological disorders. Cell Tissue Res. 2015; 360(3):609-20. DOI: 10.1007/s00441-014-2082-7. View

Kosa P, Masvekar R, Komori M, Phillips J, Ramesh V, Varosanec M . Enhancing the clinical value of serum neurofilament light chain measurement. JCI Insight. 2022; 7(15). PMC: 9462467. DOI: 10.1172/jci.insight.161415. View

Holmberg B, Johnels B, Ingvarsson P, Eriksson B, Rosengren L . CSF-neurofilament and levodopa tests combined with discriminant analysis may contribute to the differential diagnosis of Parkinsonian syndromes. Parkinsonism Relat Disord. 2001; 8(1):23-31. DOI: 10.1016/s1353-8020(00)00083-3. View

Bjornevik K, Munger K, Cortese M, Barro C, Healy B, Niebuhr D . Serum Neurofilament Light Chain Levels in Patients With Presymptomatic Multiple Sclerosis. JAMA Neurol. 2019; 77(1):58-64. PMC: 6745051. DOI: 10.1001/jamaneurol.2019.3238. View

Rissin D, Kan C, Campbell T, Howes S, Fournier D, Song L . Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. Nat Biotechnol. 2010; 28(6):595-9. PMC: 2919230. DOI: 10.1038/nbt.1641. View

Park J, Gunasekaran T, Cho Y, Choi S, Song M, Cho S . Diagnostic Blood Biomarkers in Alzheimer's Disease. Biomedicines. 2022; 10(1). PMC: 8773964. DOI: 10.3390/biomedicines10010169. View

Pauwels A, Van Schependom J, Devolder L, Van Remoortel A, Nagels G, Bjerke M . Plasma glial fibrillary acidic protein and neurofilament light chain in relation to disability worsening in multiple sclerosis. Mult Scler. 2022; 28(11):1685-1696. DOI: 10.1177/13524585221094224. View

Anderson V, Bentley E, Loveless S, Bianchi L, Harding K, Wynford-Thomas R . Serum neurofilament-light concentration and real-world outcome in MS. J Neurol Sci. 2020; 417:117079. DOI: 10.1016/j.jns.2020.117079. View

10.

Disanto G, Barro C, Benkert P, Naegelin Y, Schadelin S, Giardiello A . Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis. Ann Neurol. 2017; 81(6):857-870. PMC: 5519945. DOI: 10.1002/ana.24954. View

11.

Arroyo Pereiro P, Munoz-Vendrell A, Leon Moreno I, Bau L, Matas E, Romero-Pinel L . Baseline serum neurofilament light chain levels differentiate aggressive from benign forms of relapsing-remitting multiple sclerosis: a 20-year follow-up cohort. J Neurol. 2023; 271(4):1599-1609. PMC: 10973070. DOI: 10.1007/s00415-023-12135-w. View

12.

Liu H, Lin W, Chiu M, Lu C, Lin C, Yang S . Development of an assay of plasma neurofilament light chain utilizing immunomagnetic reduction technology. PLoS One. 2020; 15(6):e0234519. PMC: 7292381. DOI: 10.1371/journal.pone.0234519. View

13.

Steinacker P, Feneberg E, Weishaupt J, Brettschneider J, Tumani H, Andersen P . Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients. J Neurol Neurosurg Psychiatry. 2015; 87(1):12-20. DOI: 10.1136/jnnp-2015-311387. View

14.

Forgrave L, Ma M, Best J, DeMarco M . The diagnostic performance of neurofilament light chain in CSF and blood for Alzheimer's disease, frontotemporal dementia, and amyotrophic lateral sclerosis: A systematic review and meta-analysis. Alzheimers Dement (Amst). 2020; 11:730-743. PMC: 6939029. DOI: 10.1016/j.dadm.2019.08.009. View

15.

Verde F, Steinacker P, Weishaupt J, Kassubek J, Oeckl P, Halbgebauer S . Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2018; 90(2):157-164. DOI: 10.1136/jnnp-2018-318704. View

16.

De Schaepdryver M, Lunetta C, Tarlarini C, Mosca L, Chio A, Van Damme P . Neurofilament light chain and C reactive protein explored as predictors of survival in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2020; 91(4):436-437. DOI: 10.1136/jnnp-2019-322309. View

17.

Goutman S, Hardiman O, Al-Chalabi A, Chio A, Savelieff M, Kiernan M . Emerging insights into the complex genetics and pathophysiology of amyotrophic lateral sclerosis. Lancet Neurol. 2022; 21(5):465-479. PMC: 9513754. DOI: 10.1016/S1474-4422(21)00414-2. View

18.

Skillback T, Zetterberg H, Blennow K, Mattsson N . Cerebrospinal fluid biomarkers for Alzheimer disease and subcortical axonal damage in 5,542 clinical samples. Alzheimers Res Ther. 2014; 5(5):47. PMC: 3978733. DOI: 10.1186/alzrt212. View

19.

Lu C, Macdonald-Wallis C, Gray E, Pearce N, Petzold A, Norgren N . Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis. Neurology. 2015; 84(22):2247-57. PMC: 4456658. DOI: 10.1212/WNL.0000000000001642. View

20.

Hansson O, Janelidze S, Hall S, Magdalinou N, Lees A, Andreasson U . Blood-based NfL: A biomarker for differential diagnosis of parkinsonian disorder. Neurology. 2017; 88(10):930-937. PMC: 5333515. DOI: 10.1212/WNL.0000000000003680. View